Core Viewpoint - The audit report indicates that China Electronic Finance Co., Ltd. has effectively established and implemented a risk management system related to its financial statements, including funding, credit, investment, auditing, and information management as of June 30, 2025 [1][33]. Company Overview - China Electronic Finance Co., Ltd. was established as a national non-bank financial institution and began operations in 2001, with a registered capital of 1.901 billion RMB, which was later increased to 2.5 billion RMB after a capital increase [5][6]. - The company underwent a merger with Zhuhua Group Finance Co., Ltd. and opened a branch in Guizhou in May 2023 [5][6]. Risk Management System - The company has developed a comprehensive risk management system, including internal control measures and risk assessment procedures, to ensure effective governance and operational integrity [9][10]. - The internal control structure is designed to separate responsibilities among various governance bodies, including the shareholders' meeting, board of directors, and supervisory board [9]. Financial Performance - As of June 30, 2025, the company reported bank deposits of 18.666 billion RMB, net interest income of 257 million RMB, and a net profit of 161 million RMB [20][33]. - The company maintains a capital adequacy ratio of 12.75%, which exceeds the regulatory minimum requirement [20]. Compliance with Regulatory Requirements - The company adheres to the regulatory requirements set forth by the China Banking and Insurance Regulatory Commission, including maintaining liquidity ratios and limits on loan balances relative to deposits [20][21]. - The company has established various internal policies and procedures to ensure compliance with financial regulations and effective risk management [30][31].

Core Viewpoint - BGI Genomics (301269.SZ) reported a revenue of 502 million yuan for the first half of 2025, reflecting a year-on-year growth of 13.01% [2] - The net profit attributable to shareholders decreased by 91.90% to 3.0679 million yuan [2] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 18.621 million yuan, showing a year-on-year reduction in losses of 63.66% [2] - Basic earnings per share were reported at 0.0057 yuan [2] Financial Performance - Revenue for the reporting period reached 502 million yuan, marking a 13.01% increase compared to the previous year [2] - Net profit attributable to shareholders was 3.0679 million yuan, down 91.90% year-on-year [2] - The company reported a net loss of 18.621 million yuan after excluding non-recurring items, which is a 63.66% improvement in loss reduction compared to the same period last year [2] - Basic earnings per share stood at 0.0057 yuan [2]

Core Viewpoint - The company reported a revenue of 502 million yuan for the first half of 2025, reflecting a year-on-year growth of 13.01%. However, the net profit attributable to shareholders decreased significantly by 91.90% to 3.0679 million yuan [1]. Financial Performance - Revenue: 502 million yuan, up 13.01% year-on-year [1] - Net Profit: 3.0679 million yuan, down 91.90% year-on-year [1] - Net Loss (after excluding non-recurring items): 18.621 million yuan, a reduction in loss by 63.66% year-on-year [1] - Basic Earnings Per Share: 0.0057 yuan [1]

Group 1 - The company reported a revenue of 502 million yuan for the first half of 2025, representing a year-on-year growth of 13.01% [1] - The net profit attributable to shareholders of the listed company was 3.0679 million yuan, showing a significant year-on-year decline of 91.90% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -18.621 million yuan [1] - The basic earnings per share were 0.0057 yuan [1]

（文章来源：每日经济新闻） 2025年1至6月份，华大九天的营业收入构成为：集成电路行业占比100.0%。 华大九天（SZ 301269，收盘价：113.59元）8月15日晚间发布公告称，公司第二届第十八次董事会会议 于2025年8月15日在公司会议室以现场及通讯相结合的方式召开。会议审议了《关于中国电子财务有限 责任公司风险评估专项审计报告的议案》等文件。 ...

Group 1 - The company, BGI Genomics (华大九天), reported a revenue of 502 million yuan for the first half of 2025, representing a year-on-year growth of 13.01% [1] - The net profit attributable to shareholders of the listed company was 3.0679 million yuan, showing a significant decline of 91.9% compared to the previous year [1]

中国电子财务有限责任公司 专项审计报告 大信专审字[2025]第 1-01945 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2 206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F,Xueyuan International Tower No.1 Zhichun Road,Haidian Dist. Beijing,China,100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 关于中国电子财务有限责任公司 风险评估专项审计报告 大信专审字[2025]第 1-01945 号 北京华大九天科技股份有限公司： 一、审核意见 我们接受委托，审核了后附的中国电子财务有限责任公司(以下简称"中国电子财务公 司")编制的中国电子财务有限责任公司截止 2025 年 ...

上市公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | 2025 年期 | 2025 年半年度 | 2025 年半年 | 2025 年 | 2025 年 6 月 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金 | 资金占用方名称 | 占用方与上市公司的关联关系 | 上市公司 | 初占用资金 | 占用累计发生 | 度占用资金 | 半年度偿 | 30 日占用资 | 占用形成 | 占用性质 | | 占用 | | | 核算的会计科目 | 余额 | 金额 | 的利息 | 还累计发 | 金余额 | 原因 | | | | | | | | （不含利息） | （如有） | 生金额 | | | | | 控股股东、实 | | | | | | | | | | | | 际控制人及其 | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、 | | | | | | | ...

证券代码：301269 证券简称：华大九天 公告编号：2025-051 北京华大九天科技股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》及《深圳证券交易所创业板上市公司自 律监管指南第 2 号——公告格式》的规定，北京华大九天科技股份有限公司（以 下简称"公司"或"本公司"）2025 年半年度募集资金存放与实际使用情况的专 项报告如下： 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意北京华大九天科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]851 号）核准，北京华大九天科技 股份有限公司（以下简称"公司"或"本公司"）采用向社会公开发行的方式发 行人民币普通股（A 股）108,588,354 股，发行价格为每股 32.69 元。截止 2022 年 7 月 25 日，本公司实际已向社会公开发行人民 ...

北京华大九天科技股份有限公司（以下简称"公司"）第二届监事会第十四 次会议通知于 2025 年 8 月 8 日以电子邮件等方式向各位监事发出，会议于 2025 年 8 月 15 日在公司会议室以现场表决的方式召开，全体监事一致同意豁免本次 会议通知时限。本次会议应出席监事 3 人，实际出席监事 3 人，公司董事会秘书 列席本次会议。本次会议由监事会主席王博先生主持。本次会议的召集、召开及 表决程序符合《公司法》及《公司章程》的有关规定。 证券代码：301269 证券简称：华大九天 公告编号：2025-050 北京华大九天科技股份有限公司 第二届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 表决结果：赞成 2 票，反对 0 票，弃权 0 票，关联监事张凯回避表决 二、监事会会议审议情况 经与会监事审议表决，审议通过了以下议案： 1、审议通过《关于北京华大九天科技股份有限公司 2025 年半年度报告全文 及其摘要的议案》 监事会认为：董事会编制和审核《北京华大九天科技股份有限公司 2025 年 半年度报告》全文 ...